Showing results (131-140 of 436) with videos related to
Sort By:
Pageof 44
British Journal of Haematology|December 8, 2009
Characterization of Wnt/beta-catenin signalling in osteoclasts in multiple myelomaYa-Wei Qiang, Yu Chen, Nathan Brown, et al.British Journal of Haematology|October 3, 2002
Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patientsAthanasios B-T Fassas, Trey Spencer, Raman Desikan, et al.Blood|March 1, 2003
Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survivalKai-Da Wu, Lisa M Orme, John Shaughnessy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2009
Multiple Histology Phase II TrialsMichael Leblanc, Cathryn Rankin, John CrowleyStatistical Methods in Medical Research|July 4, 2002
Partitioning and peeling for constructing prognostic groupsMichael LeBlanc, Joth Jacobson, John CrowleyClinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2010
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agentsAntje Hoering, Mike LeBlanc, John CrowleyClinical Trials (London, England)|February 20, 2008
Interim futility analysis with intermediate endpointsBryan Goldman, Michael LeBlanc, John CrowleyBlood|January 18, 2003
Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expressionJohn Shaughnessy, Joth Jacobson, Jeff Sawyer, et al.Current Oncology Reports|August 22, 2012
The automatic clinical trial: leveraging the electronic medical record in multisite cancer clinical trialsKeith Goodman, Judy Krueger, John CrowleyPageof 44